718 related articles for article (PubMed ID: 19509149)
21. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
22. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
Rudolph D; Steegmaier M; Hoffmann M; Grauert M; Baum A; Quant J; Haslinger C; Garin-Chesa P; Adolf GR
Clin Cancer Res; 2009 May; 15(9):3094-102. PubMed ID: 19383823
[TBL] [Abstract][Full Text] [Related]
23. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.
He H; Zatorska D; Kim J; Aguirre J; Llauger L; She Y; Wu N; Immormino RM; Gewirth DT; Chiosis G
J Med Chem; 2006 Jan; 49(1):381-90. PubMed ID: 16392823
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
[TBL] [Abstract][Full Text] [Related]
25. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
Cai X; Zhai HX; Wang J; Forrester J; Qu H; Yin L; Lai CJ; Bao R; Qian C
J Med Chem; 2010 Mar; 53(5):2000-9. PubMed ID: 20143778
[TBL] [Abstract][Full Text] [Related]
26. NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.
Fogliatto G; Gianellini L; Brasca MG; Casale E; Ballinari D; Ciomei M; Degrassi A; De Ponti A; Germani M; Guanci M; Paolucci M; Polucci P; Russo M; Sola F; Valsasina B; Visco C; Zuccotto F; Donati D; Felder E; Pesenti E; Galvani A; Mantegani S; Isacchi A
Clin Cancer Res; 2013 Jul; 19(13):3520-32. PubMed ID: 23674492
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
28. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.
Vilenchik M; Solit D; Basso A; Huezo H; Lucas B; He H; Rosen N; Spampinato C; Modrich P; Chiosis G
Chem Biol; 2004 Jun; 11(6):787-97. PubMed ID: 15217612
[TBL] [Abstract][Full Text] [Related]
29. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
Cao X; Bloomston M; Zhang T; Frankel WL; Jia G; Wang B; Hall NC; Koch RM; Cheng H; Knopp MV; Sun D
Clin Cancer Res; 2008 Mar; 14(6):1831-9. PubMed ID: 18347186
[TBL] [Abstract][Full Text] [Related]
30. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
[TBL] [Abstract][Full Text] [Related]
31. Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors.
Musso L; Dallavalle S; Merlini L; Bava A; Nasini G; Penco S; Giannini G; Giommarelli C; De Cesare A; Zuco V; Vesci L; Pisano C; Castorina M; Milazzo F; Cervoni ML; Dal Piaz F; De Tommasi N; Zunino F
Bioorg Med Chem; 2010 Aug; 18(16):6031-43. PubMed ID: 20655237
[TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors.
Suda A; Koyano H; Hayase T; Hada K; Kawasaki K; Komiyama S; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T
Bioorg Med Chem Lett; 2012 Jan; 22(2):1136-41. PubMed ID: 22192591
[TBL] [Abstract][Full Text] [Related]
33. 15d-PGJ2 induces apoptosis by reactive oxygen species-mediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity.
Shin SW; Seo CY; Han H; Han JY; Jeong JS; Kwak JY; Park JI
Clin Cancer Res; 2009 Sep; 15(17):5414-25. PubMed ID: 19690198
[TBL] [Abstract][Full Text] [Related]
34. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
[TBL] [Abstract][Full Text] [Related]
36. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model.
Yamazaki S; Nguyen L; Vekich S; Shen Z; Yin MJ; Mehta PP; Kung PP; Vicini P
J Pharmacol Exp Ther; 2011 Sep; 338(3):964-73. PubMed ID: 21680888
[TBL] [Abstract][Full Text] [Related]
38. SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo.
Roth P; Kissel M; Herrmann C; Eisele G; Leban J; Weller M; Schmidt F
Clin Cancer Res; 2009 Nov; 15(21):6609-18. PubMed ID: 19825946
[TBL] [Abstract][Full Text] [Related]
39. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
Narla RK; Chen CL; Dong Y; Uckun FM
Clin Cancer Res; 2001 Jul; 7(7):2124-33. PubMed ID: 11448932
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
